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Pafuramidine is a novel orally active antimalarial. To identify a combination partner, we measured the in
vitro antimalarial activities of the active metabolite, DB75, with amodiaquine, artemisinin, atovaquone,
azithromycin, chloroquine, clindamycin, mefloquine, piperaquine, pyronaridine, tafenoquine, and tetracycline.
None of the drugs tested demonstrated antagonistic or synergistic activity in combination with pafuramidine.
Pafuramidine (DB289), 2,5-bis-(4-amidinophenyl)furan-bis-
O-methylamidoxime, is a promising new orally active antipar-
asitic compound (9). A recent clinical study found that pafura-
midine (200 mg/kg of body weight/day for 5 days) was effective
for 96% (22 of 23) of Plasmodium falciparum-infected patients
(9). In vivo, pafuramidine is metabolized into the active me-
tabolite 2,5-bis-(4-amidinophenyl)furan (DB75) (10, 11). Pre-
vious studies have shown that DB75 is effective against P.
falciparum, Plasmodium vivax, Pneumocystis jirovecii, Trypano-
soma brucei, and Leishmania spp. in vitro and in animal models
(2, 7).
Currently, the WHO recommends that all new antimalarial
drugs be used in combination with a second antimalarial drug
to prevent the development of resistance to monotherapy. The
two partnered drugs cannot be antagonistic and should ideally
be synergistic (8). The purpose of this study was to characterize
the interactions of the active metabolite of pafuramidine,
DB75, with potential antimalarial partner drugs.
To measure in vitro drug sensitivity, we used 42-h microdi-
lution checkerboard growth assays and cultured P. falciparum
3D7 parasites as previously described (4). Serial dilutions of
DB75 were tested in combination with serial dilutions of each
partner drug: amodiaquine, artemisinin, atovaquone, azithro-
mycin, chloroquine, clindamycin, mefloquine, piperaquine,
pyronaridine, tafenoquine, and tetracycline (3). Drug concen-
trations ranged from 5- to 10-fold above and below the prede-
termined 50% inhibitory concentration (IC50). For each part-
ner drug, the assay was repeated two or three times. The
atovaquone-proguanil combination was used to validate the
method and to determine the threshold of the sum of frac-
tional inhibitory concentrations (FIC) for synergism.
Additionally, 66-h and 96-h exposure periods were used for
select drugs (tetracycline, clindamycin, azithromycin, and taf-
enoquine) with long onsets in vitro. To measure growth in 66 h,
the methods described above were followed except that a 0.4%
parasite population was used and [3H]hypoxanthine was added
for the final 18 h of incubation. Ring cultures synchronized
with 0.3% sorbitol were used for the 96-h assay, and [3H]hy-
poxanthine was added for the final 48 h.
Results were expressed as FIC and as the mean sums of the
FIC. DB75–partner drug interactions were defined as either
indifferent (linear points on isobolograms; sum of FIC  1),
synergistic (concave curves on isobolograms; sum of FIC 
0.63) (atovaquone and proguanil), or antagonistic (convex
curves on isobolograms; sum of FIC  2.0) (1, 3).
To find a potential partner for DB75, the compound was
tested in combination with 11 current and investigational an-
timalarials. DB75 manifested indifferent relationships with 10
of the drugs tested in the 42-h assay by both the FIC and
sum-of-FIC methods (Fig. 1; Table 1). As a positive control,
atovaquone and proguanil showed clear synergy (sum of FIC 
0.63).
Three of these drugs (tetracycline, tafenoquine, and
azithromcycin) also showed indifference even with extended
incubations (Fig. 1F, D, and B, respectively; Table 1).
The clindamycin-DB75 combination was indifferent at 96 h
(Fig. 1L; Table 1). As previously reported, clindamycin alone
exhibited a biphasic dose response by the 42- and 66-h assays
(data not shown) (5). Complete inhibition was not achieved
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TABLE 1. Results for antimalarial agents in combination
with DB75
Partner drug
FIC (sum of FIC)a from the following assay:
42-h 66-h 96-h
Clindamycin N/A (N/A) N/A (N/A) I (1.09  0.16)b
Tetracycline I (0.88  0.08) I (1.04  0.19)
Atovaquone I (0.94  0.14)
Tafenoquine I (1.00  0.06) I (1.05  0.06)
Mefloquine I (1.08  0.14)
Amodiaquine I (1.09  0.03)
Artemisinin I (1.19  0.15)
Piperaquine I (1.23  0.04)
Azithromycin I (1.20  0.18) I (1.29  0.13)
Pyronaridine I (1.20  0.02)




a FIC sums are reported as means  standard deviations from two to three
assays. S, synergistic; I, indifferent; N/A, not applicable. Mean DB75 IC50s 
standard deviations are 128  51 nM at 42 h, 139  43 nM at 66 h, and 3.7 
0.76 nM at 96 h.
b Synchronized rings were used for the 96 h assay.
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with clindamycin at these times, even with hemolytic concen-
trations greater than 100 M; therefore, no IC50 could be
extrapolated for the 42- or 66-h assay. However, at 96 h, a
sigmoidal dose response was evident for clindamycin alone;
therefore, an FIC could be determined.
In summary, the lack of interaction of DB75 with either
chloroquine or atovaquone suggests that DB75 does not inter-
act with hemozoin or mitochondria in the parasite, as has been
previously suggested (6). These data also suggest that pafura-
midine could be successfully partnered with any of the 11
antimalarials tested here. Follow-up studies in animal models
are needed.
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